Sunitinib
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Sunitinib: From GIST / Renal Cell Carcinoma to Liposarcoma
One-Sentence Summary
Sunitinib is a multi-target receptor tyrosine kinase inhibitor originally used for gastrointestinal stromal tumor (GIST) and renal cell carcinoma (this evidence pack contains no Taiwan-specific approved-indication text — see Data Gaps below; the original-indication reference here is drawn from mentions within the trial descriptions in this evidence pack). The TxGNN model predicts it may also be effective for Liposarcoma, with 3 clinical trials and no dedicated publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | GIST, Renal Cell Carcinoma (inferred from trial descriptions in this evidence pack; formal Taiwan-approved indication text not available) |
| Predicted New Indication | Liposarcoma |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L2 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available in the formal drug record (flagged as a High-severity data gap, DG002). Based on the mechanistic rationale captured elsewhere in this evidence pack, Sunitinib is a multi-target receptor tyrosine kinase inhibitor that blocks VEGFR1-3, PDGFRα/β, and KIT. Its efficacy in renal cell carcinoma and GIST is well established internationally, and this same anti-angiogenic/anti-PDGFR activity is mechanistically plausible in other solid tumors that depend on these pathways.
Liposarcoma — particularly the myxoid and dedifferentiated subtypes — frequently shows angiogenesis dependence and, in a subset of cases, PDGFR pathway dysregulation, providing biological plausibility for repurposing. However, liposarcoma is not primarily driven by classic Sunitinib targets in the way GIST (KIT-driven) or clear-cell RCC (VHL/VEGF-driven) are; well-known liposarcoma drivers such as MDM2 amplification fall outside Sunitinib’s known target spectrum. As a result, the mechanistic link is assessed as moderate strength rather than direct.
Supporting this plausibility, the available trials were not designed exclusively for liposarcoma but enrolled it as part of a broader soft-tissue sarcoma (STS) population, meaning liposarcoma-specific efficacy signals are diluted within mixed-histology results.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00400569 | Phase 2 | Completed | 48 | Open-label single-site study of Sunitinib malate in unresectable/metastatic soft tissue sarcoma (leiomyosarcoma, liposarcoma, fibrosarcoma, MFH); dose given days 1–28 of a 42-day cycle. Relevance grade B — broad sarcoma umbrella trial, not liposarcoma-specific. |
| NCT00474994 | Phase 2 | Completed | 53 | Multicenter continuous-dosing study of Sunitinib in non-GIST sarcomas, including metastatic/locally advanced/recurrent disease. Relevance grade B — liposarcoma likely a subgroup, not the primary endpoint population. |
| NCT02048371 | Phase 2 | Completed | 131 | SARC024 blanket protocol studying oral kinase inhibitors across selected sarcoma subtypes. Note: the study drug tested was regorafenib, not sunitinib — relevance grade C, cannot be used as direct sunitinib evidence. |
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Currently not marketed in Taiwan (market status: Not marketed); no license/registration records are available in this evidence pack.
Cytotoxicity
Sunitinib is an antineoplastic agent (multi-target receptor tyrosine kinase inhibitor), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — multi-target receptor tyrosine kinase inhibitor (VEGFR1-3 / PDGFRα/β / KIT) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: DDI query returned 405 total interactions. Notable examples include:
- Major: Dolasetron
- Moderate: Famotidine, Loperamide, Dexamethasone, Bisacodyl, Chlorpropamide, Clarithromycin, Picosulfuric acid, Polyethylene glycol (3350 with electrolytes), Palonosetron, Glimepiride, Sodium sulfate, and multiple insulin formulations (aspart, degludec, detemir, glargine, glulisine, human isophane, human regular, inhaled rapid-acting)
Key warnings and contraindications are not available in this evidence pack (flagged as Blocking-severity data gap, DG001 — TFDA label warnings/contraindications). Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for liposarcoma specifically is limited to Phase 2 sarcoma-umbrella trials in which liposarcoma is a subgroup rather than the primary study population (Evidence Level L2, Decision Stage S2 — “Research Question”), and the mechanistic link, while plausible, is only moderate strength given liposarcoma’s typical MDM2-driven biology. Combined with the drug’s non-marketed status in Taiwan and blocking safety data gaps, this candidate is not yet ready to proceed.
To proceed, the following is needed:
- TFDA label warnings/contraindications (Blocking gap, DG001)
- Formal MOA documentation (High-priority gap, DG002)
- Liposarcoma-specific (rather than mixed-sarcoma) clinical trial or cohort data
- Taiwan regulatory/licensing pathway assessment given current “not marketed” status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.